They found that, in patients with recent-onset T2D, treatment during 14 weeks with insulin glargine or metformin compared with placebo did not reduce CRP, IL-6 and soluble tumor necrosis factor receptor 2, despite improving glucose control. Here, TNFRSF1B is linked to type 2 diabetes mellitus.